Published in Ann Rheum Dis on November 04, 2004
A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford) (2012) 3.56
The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients. Arch Dermatol Res (2006) 1.03
Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs (2014) 1.00
P-glycoprotein and drug resistance in systemic autoimmune diseases. Int J Mol Sci (2014) 0.86
Cyclosporine regimens in plaque psoriasis: an overview with special emphasis on dose, duration, and old and new treatment approaches. ScientificWorldJournal (2013) 0.80
What makes psoriatic and rheumatoid arthritis so different? RMD Open (2015) 0.80
Non-biologic disease-modifying antirheumatic drugs (DMARDs) improve pain in inflammatory arthritis (IA): a systematic literature review of randomized controlled trials. Rheumatol Int (2013) 0.78
A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2. Dermatol Ther (Heidelb) (2012) 0.77
Psoriatic arthritis: latest treatments and their place in therapy. Ther Adv Chronic Dis (2015) 0.76
Leflunomide addition in patients with articular manifestations of psoriatic arthritis resistant to methotrexate. Rheumatol Int (2012) 0.75
[Psoriatic arthritis : Overview of drug therapy options and administration characteristics]. Z Rheumatol (2016) 0.75
Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn (Stockh) (1977) 9.55
The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum (1993) 8.73
The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol (1983) 8.37
Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N Engl J Med (1995) 6.23
Severe psoriasis--oral therapy with a new retinoid. Dermatologica (1978) 5.67
Arthritis of the finger joints: a comprehensive approach comparing conventional radiography, scintigraphy, ultrasound, and contrast-enhanced magnetic resonance imaging. Arthritis Rheum (1999) 3.42
Psoriatic arthritis (PSA)--an analysis of 220 patients. Q J Med (1987) 2.80
A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford) (2003) 2.56
Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum (1997) 2.40
Classification of clinical subsets in psoriatic arthritis. Br J Rheumatol (1994) 2.13
Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med (2003) 2.12
Psoriatic arthritis: clinical response and side effects to methotrexate therapy. J Rheumatol (1992) 1.57
METHOTREXATE THERAPY IN PSORIATIC ARTHRITIS; DOUBLE-BLIND STUDY ON 21 PATIENTS. JAMA (1964) 1.56
Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum (1984) 1.46
Cyclosporine in the treatment of psoriatic arthritis. Arch Dermatol (1989) 1.41
Angiopoietins, growth factors, and vascular morphology in early arthritis. J Rheumatol (2003) 1.38
Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol (1990) 1.30
Synovitis of small joints: sonographic guided diagnostic and therapeutic approach. Ann Rheum Dis (1999) 1.22
Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: relationship to mediators of systemic and local inflammation. Arthritis Rheum (2003) 1.18
Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study. Clin Exp Rheumatol (1996) 0.99
A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol (2001) 0.93
Antiangiogenesis by cyclosporine. Exp Hematol (1998) 0.86
Methotrexate and cyclosporin combined therapy in severe psoriatic arthritis. A pilot study. Acta Derm Venereol Suppl (Stockh) (1994) 0.86
Effectiveness of psoriatic arthritis therapies. Semin Arthritis Rheum (2003) 0.83
Anti-inflammatory efficacy of low-dose cyclosporin A in psoriatic arthritis. A prospective multicentre study. Br J Dermatol (1996) 0.83
Cyclosporin A inhibition of aggrecanase-mediated proteoglycan catabolism in articular cartilage. Arthritis Rheum (2002) 0.83
T-cell-activation inhibitors in rheumatoid arthritis. BioDrugs (2003) 0.81
Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis. Br J Dermatol (1999) 0.81
Methotrexate in psoriatic arthritis: a retrospective study. Acta Derm Venereol (1983) 0.80
Clinical, immunopathogenic, and therapeutic aspects of psoriatic arthritis. Curr Opin Rheumatol (1997) 0.80
Methotrexate treatment of psoriatic arthritis. Acta Derm Venereol (1987) 0.79
Psoriatic arthritis treated with cyclosporin A. Allerg Immunol (Paris) (1992) 0.77
Short-term "cyclosporin A" therapy for psoriatic arthritis. Acta Derm Venereol Suppl (Stockh) (1994) 0.77
Therapeutic efficacy of oral low-dose cyclosporin A in severe psoriatic arthritis. Dermatology (1993) 0.77
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum (2005) 8.47
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis (2009) 8.37
Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet (1997) 6.71
EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis (2009) 5.82
The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis (2010) 5.24
Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM (1994) 5.23
Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum (2006) 5.20
A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) (2003) 4.86
EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis (2006) 4.83
The cryb mutation identifies cryptochrome as a circadian photoreceptor in Drosophila. Cell (1998) 4.81
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2011) 4.78
Classification of inflammatory arthritis by enthesitis. Lancet (1998) 4.48
The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis (2009) 4.37
Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum (1998) 4.37
An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum (2008) 4.25
Generalised bone loss in patients with early rheumatoid arthritis. Lancet (1994) 3.93
The value of sonography in the detection of bone erosions in patients with rheumatoid arthritis: a comparison with conventional radiography. Arthritis Rheum (2000) 3.85
Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis (2004) 3.64
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis (2009) 3.32
Synovial tissue inflammation in early and late osteoarthritis. Ann Rheum Dis (2005) 3.25
Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis (2008) 3.17
Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. Ann Rheum Dis (2009) 3.15
New susceptibility locus for rheumatoid arthritis suggested by a genome-wide linkage study. Proc Natl Acad Sci U S A (1998) 3.14
Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum (2006) 3.03
Musculoskeletal pain in Europe: its impact and a comparison of population and medical perceptions of treatment in eight European countries. Ann Rheum Dis (2004) 2.95
EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis (2009) 2.76
European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis (2011) 2.74
Genetic typing of patients with inflammatory arthritis at presentation can be used to predict outcome. Arthritis Rheum (1994) 2.74
Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum (2008) 2.71
Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum (2007) 2.66
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis (2008) 2.55
The therapeutic approach of early intervention for rheumatoid arthritis: what is the evidence? Rheumatology (Oxford) (2001) 2.52
Characteristic magnetic resonance imaging entheseal changes of knee synovitis in spondylarthropathy. Arthritis Rheum (1998) 2.51
Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum (2001) 2.49
Update on the use of ciclosporin in immune-mediated dermatoses. Br J Dermatol (2006) 2.49
Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis (2003) 2.48
EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis (2004) 2.48
Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis (2008) 2.45
Stopping time: the genetics of fly and mouse circadian clocks. Annu Rev Neurosci (2001) 2.44
Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis (2010) 2.40
Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum (2010) 2.37
ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis (2008) 2.37
Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomised placebo controlled trial. Ann Rheum Dis (2003) 2.34
The acute phase and function in early rheumatoid arthritis. C-reactive protein levels correlate with functional outcome. J Rheumatol (1997) 2.30
Features of the synovium of individuals at risk of developing rheumatoid arthritis: implications for understanding preclinical rheumatoid arthritis. Arthritis Rheumatol (2014) 2.28
The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2010) 2.27
New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis (2009) 2.22
Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis (2007) 2.22
How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results of 5 years of follow-up in 732 patients from the Early RA Study (ERAS) Rheumatology (Oxford) (2000) 2.21
Large air leak from an endotracheal tube due to a manufacturing defect. Anesth Analg (1997) 2.20
Interleukin-2 reverses deficient cell-mediated immune responses in rheumatoid arthritis. Clin Exp Immunol (1984) 2.17
A randomised comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment. Ann Rheum Dis (2004) 2.12
Which patients stop working because of rheumatoid arthritis? Results of five years' follow up in 732 patients from the Early RA Study (ERAS). Ann Rheum Dis (2002) 2.11
EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis (2010) 2.09
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. Arthritis Rheum (2008) 2.07
Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis (2006) 2.07
A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study. Rheumatology (Oxford) (2005) 2.05
Effect of vitamin D receptor gene alleles on bone loss in early rheumatoid arthritis. J Rheumatol (1998) 2.05
Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ (1996) 2.04
Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann Rheum Dis (2002) 2.02
Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy. Eur Respir J (2009) 2.01
Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis (2008) 2.01
Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative. Ann Rheum Dis (2011) 1.97
Osteoclastic activation is the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis. J Rheumatol (1998) 1.97
Prescribing in the UK. Lancet (2001) 1.93
Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis (2003) 1.91
Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. Arthritis Rheum (2007) 1.90
EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis (2007) 1.90
Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis (2009) 1.90
An introduction to the EULAR-OMERACT rheumatoid arthritis MRI reference image atlas. Ann Rheum Dis (2005) 1.89
Inhibition of T cell apoptosis in the rheumatoid synovium. J Clin Invest (1997) 1.89
Subpopulations of primed T helper cells in rheumatoid arthritis. Arthritis Rheum (1993) 1.88
High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann Rheum Dis (2007) 1.87
DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis. Ann Rheum Dis (2010) 1.87
Local and systemic glucocorticoid metabolism in inflammatory arthritis. Ann Rheum Dis (2008) 1.86
Combined spa-exercise therapy is effective in patients with ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum (2001) 1.86
Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial. Ann Rheum Dis (2007) 1.86
Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. Ann Rheum Dis (2005) 1.85
Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis (2008) 1.84
An anatomical explanation for good-prognosis rheumatoid arthritis. Lancet (1999) 1.84
Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis (2004) 1.84
Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study. Arthritis Rheum (2011) 1.83
Should oligoarthritis be reclassified? Ultrasound reveals a high prevalence of subclinical disease. Ann Rheum Dis (2004) 1.82
Microdamage and altered vascularity at the enthesis-bone interface provides an anatomic explanation for bone involvement in the HLA-B27-associated spondylarthritides and allied disorders. Arthritis Rheum (2007) 1.80
Simultaneous development of acute phase response and autoantibodies in preclinical rheumatoid arthritis. Ann Rheum Dis (2005) 1.80
Classical versus non-renal Wegener's granulomatosis. Q J Med (1994) 1.79
A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study. Ann Rheum Dis (2010) 1.79
Targeted therapies in rheumatoid arthritis: the need for action. Rheumatology (Oxford) (1999) 1.78
The relationship between synovitis and bone changes in early untreated rheumatoid arthritis: a controlled magnetic resonance imaging study. Arthritis Rheum (1999) 1.78